TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11741108

Group type: EXPERIMENTAL
Intervention: Oral single-dose (20 mg) ketanserin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9212953

Group type: EXPERIMENTAL
Intervention: HPM‐15 (Nikkiso Co.)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Capiox (Terumo Co.)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lifestream (St. Jude Medical Co.)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: BP‐80 (Medtronic, BioMedicus Co.)
Number of subjects: 4
Study: 8219660

Group type: EXPERIMENTAL
Intervention: Fish oil (9 g daily for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Olive oil (9 g daily for 6 weeks)
Number of subjects: 10
Study: 2887475

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) + cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 0
Study: 29283450

Group type: EXPERIMENTAL
Intervention: Fasting samples
Number of subjects: 4177

Group type: COMPARATOR
Intervention: Non-fasting samples
Number of subjects: 4177
Study: 26271931

Group type: EXPERIMENTAL
Intervention: Resistance training (RET) for 8 weeks
Number of subjects: 21
Study: 24980467

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (two‐ or three‐dose primary infant series plus a single toddler dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (three‐dose infant primary series)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (two‐dose toddler catch‐up series)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine with concomitant routine vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (three‐dose infant series)
Number of subjects: 0
Study: 22234287

Group type: EXPERIMENTAL
Intervention: High-speed power training (40% to 75% of 1RM); 3 sets of 4-12 reps, countermovement jump, and 1.5 kg medicine ball throwing
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study: 20369277

Group type: EXPERIMENTAL
Intervention: Early Intervention (EI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early Intervention with Work Transition (EI/WT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study: 19192856

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) during standard care
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care without CM
Number of subjects: 75
Study: 16996947

Group type: EXPERIMENTAL
Intervention: Piracetam (150 mg/kg daily; 300 mg/kg on the day of surgery, then orally 12 g/day up to 6 weeks after surgery)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 98
Study: 12974696

Group type: EXPERIMENTAL
Intervention: S-Caine Peel (30-minute application)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream (30-minute application)
Number of subjects: 20
Study: 11004038

Group type: COMPARATOR
Intervention: General anesthesia (propofol-nitrous oxide with laryngeal mask airway, anesthetic depth titrated to bispectral index level of 40-60)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epidural anesthesia (15-20 mL of 3% 2-chloroprocaine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (75 mg of subarachnoid procaine with 20 microg fentanyl)
Number of subjects: 48
Study: 8837407

Group type: EXPERIMENTAL
Intervention: Hypnosis during recall
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waking during recall
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Visualization ability
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: High imagery recall
Number of subjects: 82
Study: 1330962

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg for three days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6383049

Group type: EXPERIMENTAL
Intervention: Full physical activity immediately after hospital discharge
Number of subjects: 108

Group type: COMPARATOR
Intervention: Strictly forbidden physical activities for six weeks
Number of subjects: 108
Study: 31842771

Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 5% gel
Number of subjects: 40
Study: 28994035

Group type: EXPERIMENTAL
Intervention: SurvivorCHESS eHealth intervention
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study: 26987963

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional rehabilitation therapies
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapies
Number of subjects: 60
Study: 24582111

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 54
Study: 22486133

Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus midazolam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline plus midazolam
Number of subjects: 36
Study: 20451192

Group type: EXPERIMENTAL
Intervention: Combined approach of diagnostic hysteroscopy and endometrial sampling during oral contraceptive pill treatment followed by ultrashort GnRH‐ag/GnRH‐ant protocol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Previous failed IVF attempt
Number of subjects: 19
Study: 18630768

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non BIS (control group)
Number of subjects: 30
Study: 16138560

Group type: EXPERIMENTAL
Intervention: Candesartan (2 to 12 mg daily)
Number of subjects: 2048

Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs
Number of subjects: 2048
Study: 11809430

Group type: EXPERIMENTAL
Intervention: Aspirin (acetylsalicylic acid [ASA], 1, 3, and 10 mg/min)
Number of subjects: 71
Study: 10640079

Group type: EXPERIMENTAL
Intervention: StatLock i.v. securement device
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard securement technique
Number of subjects: 2
Study: 8552739

Group type: EXPERIMENTAL
Intervention: Sensory focus with procedural information
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Sensory focus without procedural information
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Procedural information
Number of subjects: 303

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 303
Study: 2014890

Group type: EXPERIMENTAL
Intervention: Alkalinised bupivacaine with adrenaline 1:200,000 (pH = 6.9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine with adrenaline 1:200,000 (pH = 4.1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Alkalinised and non-alkalinised bupivacaine)
Number of subjects: 20
Study: 6294796

Group type: EXPERIMENTAL
Intervention: Cefotaxime (20 mg/kg IV every 6 hr)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Gentamicin plus Clindamycin (1 mg/kg gentamicin IV every 8 hr plus 5 mg/kg clindamycin IV every 6 hr)
Number of subjects: 112
Study: 31063870

Group type: EXPERIMENTAL
Intervention: Basic Implementation Intervention (access to RxWL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Intervention (access to RxWL with additional training and support)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monthly Lessons (within RxWL patient platform)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Refresher Courses (within RxWL patient platform)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 60
Study: 28504031

Group type: EXPERIMENTAL
Intervention: Topical 0.25% desoximetasone spray
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26661397

Group type: EXPERIMENTAL
Intervention: Fasted state for isoniazid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fed state for isoniazid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasted state for rifampicin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fed state for rifampicin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasted state for ethambutol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fed state for ethambutol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasted state for pyrazinamide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fed state for pyrazinamide
Number of subjects: 20
Study: 22928741

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative PET review
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quantitative analysis with SUV thresholds
Number of subjects: 100
Study: 21610189

Group type: EXPERIMENTAL
Intervention: Sheltered workshops
Number of subjects: 430

Group type: COMPARATOR
Intervention: Not in sheltered workshops
Number of subjects: 430
Study: 21175030

Group type: EXPERIMENTAL
Intervention: Group B (3M Unitek - small base)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group A (American Orthodontics)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group D (Hangzhou Dentop)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group C (3M Unitek - large base)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Groups A and B
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups except A and B
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All buccal tubes
Number of subjects: 80
Study: 17982122

Group type: EXPERIMENTAL
Intervention: Ipilimumab in conjunction with peptide vaccinations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Intra-patient dose escalation of ipilimumab
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Development of immune-related adverse events (IRAE)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Prior therapy with IFNalpha-2b
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Prior high-dose interleukin-2
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Use of high-dose steroids for treatment-related toxicities
Number of subjects: 139
Study: 15525928

Group type: EXPERIMENTAL
Intervention: Ege's test for medial meniscal lesions
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Joint Line Tenderness (JLT) for medial meniscal lesions
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ege's test for lateral meniscal tears
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: McMurray's test for medial meniscal lesions
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: McMurray's test for lateral meniscal tears
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Joint Line Tenderness (JLT) for lateral meniscal tears
Number of subjects: 150

Group type: COMPARATOR
Intervention: All tests (Ege's, McMurray's, JLT)
Number of subjects: 150
Study: 11549530

Group type: EXPERIMENTAL
Intervention: Long-acting beta(2)-agonists (formoterol) with inhaled corticosteroids
Number of subjects: 94

Group type: COMPARATOR
Intervention: Short-acting beta(2)-agonists (salbutamol)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 9740164

Group type: EXPERIMENTAL
Intervention: Multidose formulation of epoetin alfa
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single-dose formulation of epoetin alfa
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 28
Study: 8113548

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3123540

Group type: EXPERIMENTAL
Intervention: Cromolyn 20 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Terbutaline 0.1 mg/kg up to 4 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of cromolyn and terbutaline
Number of subjects: 27
Study: 30832548

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 185

Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen
Number of subjects: 185
Study: 29231470

Group type: EXPERIMENTAL
Intervention: Mild moxibustion with moxa stick applied to Guanyuan (CV 4), Zusanli (ST 36) and Sanyinjiao (SP 6), once every other day for 2 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mild moxibustion group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medication group (yupingfeng granules prescribed for oral administration, three times a day for 2 months)
Number of subjects: 72
Study: 26233501

Group type: EXPERIMENTAL
Intervention: TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%
Number of subjects: 60

Group type: COMPARATOR
Intervention: LD (n = 30)
Number of subjects: 60
Study: 23876561

Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21641819

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of remifentanil (target: 7 ng/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous infusion (CI) of remifentanil (0.3 μg/kg/min)
Number of subjects: 40
Study: 20023610

Group type: EXPERIMENTAL
Intervention: Printed information supplied in the form of anticipatory guidance (3 rounds)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 649
Study: 15287307

Group type: EXPERIMENTAL
Intervention: LactoSorb (resorbable osteosynthesis material)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Titanium osteosynthesis
Number of subjects: 60
Study: 10399633

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2‐mmol/kg intravenous bolus)
Number of subjects: 0
Study: 8570858

Group type: EXPERIMENTAL
Intervention: Deltorphin (DT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arginine (ARG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Galanin (GAL)
Number of subjects: 0
Study: 2246974

Group type: EXPERIMENTAL
Intervention: met‐hGH (16.0 mg/wk of Protropin)
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo (bacteriostatic water)
Number of subjects: 7
Study: 6258116

Group type: EXPERIMENTAL
Intervention: ACO I and ACO II protocols
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ACO II protocol (maintenance therapy after aggressive induction treatment)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 94
Study: 31090458

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 (2.5×10^9 cfu/capsule)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis B94 (5×10^9 cfu/capsule)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 27918846

Group type: EXPERIMENTAL
Intervention: Soy food consumption (2 daily servings)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Soy diet
Number of subjects: 316

Group type: COMPARATOR
Intervention: Soy food consumption
Number of subjects: 316
Study: 26567264

Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder in larger classrooms
Number of subjects: 334

Group type: COMPARATOR
Intervention: Typically developing boys in larger classrooms
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder
Number of subjects: 334
Study: 25012265

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) only
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: IPC plus enoxaparin
Number of subjects: 220

Group type: COMPARATOR
Intervention: IPC only
Number of subjects: 220
Study: 22873207

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Watson‐Jones Approach (WJA)
Number of subjects: 60
Study: 19617863

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study: 17886253

Group type: EXPERIMENTAL
Intervention: Atrasentan 10 mg per day
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study: 15282985

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 30 ml of ropivacaine 7.5 mg/ml
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pharmacological treatment only (Paracetamol and tramadol)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 80
Study: 11337303

Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, and 100 mg)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 9849708

Group type: EXPERIMENTAL
Intervention: Open vaginal cuff technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Closed vaginal cuff technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study: 8003642

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg every morning
Number of subjects: 250

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg every morning and at bedtime
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 250
Study: 2583918

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10, 20, 40 mg
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study: 31386273

Group type: EXPERIMENTAL
Intervention: Topiramate 125 mg daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30629330

Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (iCT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Postoperative MRI
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (iCT) and Postoperative MRI
Number of subjects: 29
Study: 28357504

Group type: EXPERIMENTAL
Intervention: GAD-alum (two doses)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: GAD-alum (four doses)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 25998572

Group type: EXPERIMENTAL
Intervention: Extended-release aspirin (ER-ASA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immediate-release aspirin (IR-ASA)
Number of subjects: 50
Study: 24147073

Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study: 21859401

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2080 mg daily for 10 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19670623

Group type: EXPERIMENTAL
Intervention: Bithermal test before PRM
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bithermal test after PRM
Number of subjects: 96
Study: 18085141

Group type: EXPERIMENTAL
Intervention: Ear point taping and pressing therapy combined with acupoint-injection
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine western medicine (medication group)
Number of subjects: 116
Study: 15181487

Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg thrice daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Acyclovir 800 mg 5 times daily
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 55

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 55
Study: 12177566

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Basic Case Management (BCM)
Number of subjects: 159
Study: 9716311

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 8083368

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg t.i.d.) during high salt diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo during high salt diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High salt diet (UNaV > 200 meq/d)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low salt diet (UNaV < 50 meq/d)
Number of subjects: 19
Study: 2574052

Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15825310

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 10
Study: 31943293

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 31228136

Group type: EXPERIMENTAL
Intervention: Side-to-End Anastomosis (SEA)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Colon J-Pouch (CJP)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Straight Colorectal Anastomosis (SCA)
Number of subjects: 336
Study: 28859790

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 116
Study: 24913131

Group type: EXPERIMENTAL
Intervention: IPL-PDT using 0.5% 5-aminolevulinic acid liposomal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long pulsed Nd:YAG laser (LPNY)
Number of subjects: 0
Study: 23307112

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 1.3 × 10(10) CFU Lactobacillus casei Shirota (LcS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Skimmed milk (placebo)
Number of subjects: 30
Study: 20847562

Group type: EXPERIMENTAL
Intervention: Oral budesonide
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Microalbuminuria presence during relapse
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 139
Study: 18269155

Group type: EXPERIMENTAL
Intervention: Sub-Bowman's keratomileusis (SBK)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 50
Study: 16772251

Group type: EXPERIMENTAL
Intervention: Supervised home-based aerobic and progressive resistance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40